Medtronic stock gains focus as ablation data support growth

Published on 11/04/2026 at 12:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medtronic stock is in focus after positive real-world registry findings for two cardiac ablation systems. The data support its cardiovascular portfolio.

Registry data strengthen cardiac portfolio

Medtronic reported positive real-world results for Sphere-9 and PulseSelect at the APHRS 2026 meeting.
Management said the findings support the safety and performance of its ablation technologies.
The data add clinical support to Medtronic's cardiovascular business after the MiniMed separation.

Medtronic plc, IE00BTN1Y115, Illustration mit AI erstellt.

Medtronic reported positive real-world registry results for two cardiac ablation systems on October 22, 2026, with findings presented at the Asia Pacific Heart Rhythm Society meeting. The company's Medtronic press release covered the Affera Mapping and Ablation System with the Sphere-9 catheter and the PulseSelect pulsed field ablation system.

Medtronic stock traded at 88.44 euros on Lang & Schwarz at 12:07 CET on Wednesday, November 4, 2026. Investors are weighing the clinical evidence alongside the company's portfolio shift toward cardiovascular, neuroscience and surgical businesses following the completed MiniMed separation.

Evidence from two registries

The global APEX registry analysis included 1,050 patients with atrial fibrillation treated with Sphere-9 and the Affera system at 28 sites. Medtronic reported a 1.1% major complication rate, with no acute kidney injury, severe coronary spasm or phrenic nerve injury. Major complication rates did not differ significantly between first-time and repeat ablation procedures.

The REAL PULSE registry covered 1,160 atrial fibrillation patients treated with PulseSelect at 38 global sites. The analysis recorded a 100% acute success rate and an acute major complication rate of 0.09%, according to the company.

Additional data in ventricular care

A separate European APEX analysis evaluated Sphere-9 in 46 patients undergoing treatment for sustained ventricular tachycardia. Acute success reached 87%, while estimated freedom from ventricular tachycardia recurrence at six months was 75%. Six major complications were reported in four patients.

Medtronic said the results reinforce confidence in the safety and performance of its ablation technologies. Khaldoun Tarakji, the company's vice president of science, research and technology for electrophysiology therapies, said the findings reflected encouraging physician response and real-world evidence across a broad range of arrhythmias. Felicia Kurz, vice president and general manager of Cardiac Ablation Solutions, said the company would continue developing care that is safe, effective and efficient.

The findings strengthen the clinical case for Medtronic's electrophysiology portfolio, but registry results alone do not establish a revenue forecast. Sphere-9 combines high-definition mapping with pulsed field and radiofrequency ablation through the Affera platform, while PulseSelect is designed as a single-shot system for pulmonary vein isolation. Medtronic states that Sphere-9 is CE marked for ventricular tachycardia but remains investigational and not approved for that indication in the United States.

Investors can follow the real-time quote of Medtronic stock as the market assesses whether cardiovascular momentum can offset changes in the diabetes portfolio.

The S&P 500 provides the broader US market context for healthcare shares.

For further developments, see More news and analyses on Medtronic stock.